Abstract
Purpose
Although the outcome of surgery for locally advanced pancreatic cancer remains poor, it is improving, with 5-year survival up to about 10% in Japan. The preliminary results of our multi-institutional randomized controlled trial revealed better survival after surgery than after radiochemotherapy. We report the final results of this study after 5 years of follow-up.
Methods
Patients with preoperative findings of pancreatic cancer invading the pancreatic capsule without involvement of the superior mesenteric or common hepatic arteries, or distant metastasis, were included in this randomized controlled trial, with their consent. If the laparotomy findings were consistent with these criteria, the patient was randomized to a surgery group or a radiochemotherapy group (5-fluorouracil 200 mg/m2/day and 5040 Gy radiotherapy). We compared the mean survival time, 3-and 5-year survival rates, and hazard ratio.
Results
The surgery and radiochemotherapy groups comprised 20 and 22 patients, respectively. Patients were followed up for 5 years or longer, or until an event occurred to preclude this. The surgery group had significantly better survival than the radiochemotherapy group (P < 0.03). Surgery increased the survival time and 3-year survival rate by an average of 11.8 months and 20%, respectively, and it halved the instantaneous mortality (hazard) rate.
Conclusion
Locally invasive pancreatic cancer without distant metastases or major arterial invasion is treated most effectively by surgical resection.
Similar content being viewed by others
References
Fortner JG, Kim DK, Cubilla A, Turnbull A, Pahnke LD, Shils ME. Regional pancreatectomy: en bloc pancreatic, portal vein and lymph node resection. Ann Surg 1977;186:42–50.
Nagakawa T, Nagamori M, Futakami F, Tsukioka Y, Kayahara M, Ohta T, et al. Results of extensive surgery for pancreatic carcinoma. Cancer 1996;77:640–645.
Imaizumi T, Hanyu F, Harada N, Hatori T, Fukuda A. Extended radical Whipple resection for cancer of the pancreatic head: operative procedure and results. Dig Surg 1998;15:299–307.
Yamamoto M, Ohashi O, Saitoh Y. Japan Pancreatic Cancer Registry: current status. Pancreas 1998;16:238–242.
Pancreatic Cancer Registration Committee of the Japan Pancreas Society. Report of a nation-wide survey of pancreatic cancer in 1999 (Japanese). Suizou (J Jap Pancreas Soc) 2001;16:115–147.
Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993;217:430–435.
Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990;211:447–458.
Livingston EH, Welton ML, Reber HA. Surgical treatment of pancreatic cancer. The United States experience. Int J Pancreatol 1991;9:153–157.
Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995;221:59–66.
Meyer W, Jurowich C, Reichel M, Steinhauser B, Wunsch PH, Gebhardt C. Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas. Surg Today 2000;30:582–587.
Ozaki H, Hiraoka T, Mizumoto R, Matsuno S, Matsumoto Y, Nakayama T, et al. The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 1999;29:16–22.
Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995;76:1671–1677.
Schafer M, Mullhaupt B, Clavien PA. Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg 2002;236:137–148.
Kelsen D. The use of chemotherapy in the treatment of advanced gastric and pancreas cancer. Semin Oncol 1994;21:58–66.
Fennelly D, Kelsen DP. The role of chemotherapy in the treatment of adenocarcinoma of the pancreas. Hepatogastroenterology 1996;43:356–362.
Riess H, Htun P, Loffel J, Huhn D. Chemotherapy for patients with adenocarcinoma of the pancreas. Recent Results Cancer Res 1996;142:415–424.
Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899–903.
Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865–867.
Moertel CG, Frytak S, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705–1710.
Imamura M, Doi R, Imaizumi T, Funakoshi A, Wakasugi H, Sunamura M, et al. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery 2004;136:1003–1011.
Japan Pancreas Society. Classification of pancreatic carcinoma (English edition). 1st ed. Tokyo: Kanehara, 1996.
Wright JC, Weinstein MC. Gains in life expectancy from medical interventions — standardizing data on outcomes. N Engl J Med 1998;339:380–386.
Tan LB, Murphy R. Shifts in mortality curves: saving or extending lives? Lancet 1999;354:1378–1381.
Beard SM, Holmes M, Price C, Majeed AW. Hepatic resection for colorectal liver metastases: a cost-effectiveness analysis. Ann Surg 2000;232:763–776.
Karrison TG. Use of Irwin’s restricted mean as an index for comparing survival in different treatment groups — interpretation and power considerations. Control Clin Trials 1997;18:151–167.
Irwin JO. The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice. J Hygiene 1949;47:188–189.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
Kurihara M, Shimizu H, Tsuboi K, Kobayashi K, Murakami M, Eguchi K, et al. Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 1999;8:355–363.
DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999;117:1464–1484.
Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg 1999;189:1–7.
Gordon TA, Burleyson GP, Tielsch JM, Cameron JL. The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg 1995;221:43–49.
Glasgow RE, Mulvihill SJ. Hospital volume influences outcome in patients undergoing pancreatic resection for cancer. West J Med 1996;165:294–300.
Gouma DJ, van Geenen RC, van Gulik TM, de Haan RJ, de Wit LT, Busch OR, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 2000;232:786–795.
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–1210.
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267–277.
Inoue K, Hiraoka T, Kanemitsu K, Takamori H, Tsuji T, Kawasuji M. Onset of liver metastasis after histologically curative resection of pancreatic cancer. Surg Today 2006;36:252–256.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Doi, R., Imamura, M., Hosotani, R. et al. Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: Final results of a randomized multi-institutional trial. Surg Today 38, 1021–1028 (2008). https://doi.org/10.1007/s00595-007-3745-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00595-007-3745-8